CN1291231A - 人类的端粒酶催化亚单位 - Google Patents
人类的端粒酶催化亚单位 Download PDFInfo
- Publication number
- CN1291231A CN1291231A CN97180256A CN97180256A CN1291231A CN 1291231 A CN1291231 A CN 1291231A CN 97180256 A CN97180256 A CN 97180256A CN 97180256 A CN97180256 A CN 97180256A CN 1291231 A CN1291231 A CN 1291231A
- Authority
- CN
- China
- Prior art keywords
- htrt
- cell
- telomerase
- sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 title claims abstract description 518
- 108010017842 Telomerase Proteins 0.000 claims abstract description 356
- 238000000034 method Methods 0.000 claims abstract description 287
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 222
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 184
- 229920001184 polypeptide Polymers 0.000 claims abstract description 183
- 239000002157 polynucleotide Substances 0.000 claims abstract description 164
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 164
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 164
- 239000000203 mixture Substances 0.000 claims abstract description 137
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 201000010099 disease Diseases 0.000 claims abstract description 46
- 230000003197 catalytic effect Effects 0.000 claims abstract description 45
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 238000012216 screening Methods 0.000 claims abstract description 22
- 238000003745 diagnosis Methods 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 414
- 108090000623 proteins and genes Proteins 0.000 claims description 318
- 102000004169 proteins and genes Human genes 0.000 claims description 184
- 235000018102 proteins Nutrition 0.000 claims description 179
- 150000007523 nucleic acids Chemical group 0.000 claims description 111
- 102000039446 nucleic acids Human genes 0.000 claims description 109
- 108020004707 nucleic acids Proteins 0.000 claims description 109
- 108020004414 DNA Proteins 0.000 claims description 99
- 230000014509 gene expression Effects 0.000 claims description 99
- 239000002773 nucleotide Substances 0.000 claims description 98
- 125000003729 nucleotide group Chemical group 0.000 claims description 98
- 230000000694 effects Effects 0.000 claims description 97
- 239000000047 product Substances 0.000 claims description 97
- 238000012360 testing method Methods 0.000 claims description 92
- 230000004913 activation Effects 0.000 claims description 89
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 77
- 108091035539 telomere Proteins 0.000 claims description 68
- 108091034117 Oligonucleotide Proteins 0.000 claims description 67
- 102000055501 telomere Human genes 0.000 claims description 66
- 239000000523 sample Substances 0.000 claims description 64
- 201000011510 cancer Diseases 0.000 claims description 58
- 210000003411 telomere Anatomy 0.000 claims description 56
- 230000008859 change Effects 0.000 claims description 54
- 230000008521 reorganization Effects 0.000 claims description 43
- 239000012634 fragment Substances 0.000 claims description 41
- 230000000692 anti-sense effect Effects 0.000 claims description 38
- 239000003153 chemical reaction reagent Substances 0.000 claims description 38
- 108020004999 messenger RNA Proteins 0.000 claims description 38
- 108010057210 telomerase RNA Proteins 0.000 claims description 36
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 34
- 230000003321 amplification Effects 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 30
- 210000001519 tissue Anatomy 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 26
- 230000004927 fusion Effects 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 238000009396 hybridization Methods 0.000 claims description 25
- 101150111242 TPT1 gene Proteins 0.000 claims description 23
- 230000008676 import Effects 0.000 claims description 23
- 108060005986 Granzyme Proteins 0.000 claims description 22
- 102000001398 Granzyme Human genes 0.000 claims description 22
- 238000001415 gene therapy Methods 0.000 claims description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 20
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 15
- 238000012544 monitoring process Methods 0.000 claims description 15
- 210000005260 human cell Anatomy 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 13
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000000470 constituent Substances 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 230000001093 anti-cancer Effects 0.000 claims description 7
- 230000003211 malignant effect Effects 0.000 claims description 7
- 230000006798 recombination Effects 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 6
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 239000002777 nucleoside Substances 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 3
- 210000002826 placenta Anatomy 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000004422 calculation algorithm Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- 108090001008 Avidin Proteins 0.000 claims 2
- 238000003149 assay kit Methods 0.000 claims 2
- 238000006555 catalytic reaction Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 229930003756 Vitamin B7 Natural products 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 230000009871 nonspecific binding Effects 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 238000005204 segregation Methods 0.000 claims 1
- 239000011735 vitamin B7 Substances 0.000 claims 1
- 235000011912 vitamin B7 Nutrition 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 abstract description 16
- 102000002067 Protein Subunits Human genes 0.000 abstract description 16
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 134
- 239000002987 primer (paints) Substances 0.000 description 134
- 238000001994 activation Methods 0.000 description 82
- 239000002299 complementary DNA Substances 0.000 description 33
- 102100031780 Endonuclease Human genes 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 30
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 26
- 230000006870 function Effects 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 241000700605 Viruses Species 0.000 description 22
- 235000013339 cereals Nutrition 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 22
- 108060003951 Immunoglobulin Proteins 0.000 description 20
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 20
- 102000018358 immunoglobulin Human genes 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 18
- 102000029724 enzyme binding proteins Human genes 0.000 description 18
- 108091009282 enzyme binding proteins Proteins 0.000 description 18
- 239000002585 base Substances 0.000 description 16
- 108090000994 Catalytic RNA Proteins 0.000 description 15
- 102000053642 Catalytic RNA Human genes 0.000 description 15
- 108091092562 ribozyme Proteins 0.000 description 15
- 241000248499 Euplotes aediculatus Species 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 14
- 239000000074 antisense oligonucleotide Substances 0.000 description 14
- 238000012230 antisense oligonucleotides Methods 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 230000002103 transcriptional effect Effects 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 108700026244 Open Reading Frames Proteins 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 230000014616 translation Effects 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 241000248488 Euplotes Species 0.000 description 11
- 102000005720 Glutathione transferase Human genes 0.000 description 11
- 108010070675 Glutathione transferase Proteins 0.000 description 11
- 241000248384 Tetrahymena thermophila Species 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 10
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 10
- 235000007708 morin Nutrition 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 108020005038 Terminator Codon Proteins 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000005336 cracking Methods 0.000 description 9
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000001293 nucleolytic effect Effects 0.000 description 7
- 108010001515 Galectin 4 Proteins 0.000 description 6
- 102100039556 Galectin-4 Human genes 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000009165 androgen replacement therapy Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- -1 methane amide Chemical class 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 238000001261 affinity purification Methods 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000032677 cell aging Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 5
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000037433 frameshift Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000002853 nucleic acid probe Substances 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000723873 Tobacco mosaic virus Species 0.000 description 4
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 208000021267 infertility disease Diseases 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Chemical group 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 208000005927 Myosarcoma Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 241000710961 Semliki Forest virus Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 3
- 210000004671 cell-free system Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000006854 communication Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 201000005649 gangliocytoma Diseases 0.000 description 3
- 201000008361 ganglioneuroma Diseases 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002969 morbid Effects 0.000 description 3
- 201000002077 muscle cancer Diseases 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- CZGGKXNYNPJFAX-UHFFFAOYSA-N Dimethyldithiophosphate Chemical compound COP(S)(=S)OC CZGGKXNYNPJFAX-UHFFFAOYSA-N 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 108010025076 Holoenzymes Proteins 0.000 description 2
- 101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 2
- 101000679525 Homo sapiens Two pore channel protein 2 Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 241000248501 Oxytricha Species 0.000 description 2
- 241000465782 Oxytricha trifallax Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710192266 Tegument protein VP22 Proteins 0.000 description 2
- 102100024553 Telomerase protein component 1 Human genes 0.000 description 2
- 102000010823 Telomere-Binding Proteins Human genes 0.000 description 2
- 108010038599 Telomere-Binding Proteins Proteins 0.000 description 2
- 241000223892 Tetrahymena Species 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000255985 Trichoplusia Species 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100022609 Two pore channel protein 2 Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- 230000003679 aging effect Effects 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 208000001611 myxosarcoma Diseases 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000000583 Adenolymphoma Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- NTTIDCCSYIDANP-UHFFFAOYSA-N BCCP Chemical compound BCCP NTTIDCCSYIDANP-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 208000003609 Bile Duct Adenoma Diseases 0.000 description 1
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 1
- 101710180532 Biotin carboxyl carrier protein of acetyl-CoA carboxylase Proteins 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000007389 Cementoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010008642 Cholesteatoma Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 101100087110 Enterobacteria phage T4 repEA gene Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 206010018381 Glomus tumour Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001006375 Homo sapiens High mobility group nucleosome-binding domain-containing protein 4 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-Glutamic acid Natural products OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000008095 Malignant Carcinoid Syndrome Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000010153 Mesonephroma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 102000011244 Nuclear receptor coactivator Human genes 0.000 description 1
- 108050001461 Nuclear receptor coactivator Proteins 0.000 description 1
- 102000002488 Nucleoplasmin Human genes 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000412292 Pandita Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
- 101150052131 Pgap2 gene Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 101150104269 RT gene Proteins 0.000 description 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101710203837 Replication-associated protein Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 108020003564 Retroelements Proteins 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 101100477602 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIR3 gene Proteins 0.000 description 1
- 101100477614 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIR4 gene Proteins 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042658 Sweat gland tumour Diseases 0.000 description 1
- 229940123582 Telomerase inhibitor Drugs 0.000 description 1
- 108010033711 Telomeric Repeat Binding Protein 1 Proteins 0.000 description 1
- 102000007316 Telomeric Repeat Binding Protein 2 Human genes 0.000 description 1
- 108010033710 Telomeric Repeat Binding Protein 2 Proteins 0.000 description 1
- 102100036497 Telomeric repeat-binding factor 1 Human genes 0.000 description 1
- 102100038346 Telomeric repeat-binding factor 2-interacting protein 1 Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 208000021146 Warthin tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 201000009431 angiokeratoma Diseases 0.000 description 1
- 208000000252 angiomatosis Diseases 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000021592 benign granular cell tumor Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- ININOGTZHQOEKR-UHFFFAOYSA-N carbamic acid;morpholine Chemical compound NC(O)=O.C1COCCN1 ININOGTZHQOEKR-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 208000005761 carcinoid heart disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 101150024138 dbpB gene Proteins 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002058 ecdysones Chemical class 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 201000005133 hidradenoma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000011831 mesonephric neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000004130 myoblastoma Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108060005597 nucleoplasmin Proteins 0.000 description 1
- 102000026415 nucleotide binding proteins Human genes 0.000 description 1
- 108091014756 nucleotide binding proteins Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000004049 perilymph Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 108010028349 saliva Orthana Proteins 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013456 study Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Abstract
Description
组分 | 蛋白质(毫克) | 端粒酶(RNP的皮摩尔) | 端粒酶/蛋白质/皮摩尔RNP/毫克 | 回收率(%) | 纯化因子 |
核提取物 | 2020 | 1720 | 0.9 | 100 | 1 |
肝素 | 125 | 1040 | 8.3 | 60 | 10 |
亲和性 | 0.3** | 680 | 2270 | 40 | 2670 |
甘油梯度 | NA* | NA** | NA* | 25 | NA* |
泳道 | 引物序列(5’至3’) |
1-3 | C4(A4C4)3CACA(G4T4)3G4 |
4-6 | C2(A4C4)3CACA(G4T4)3G4 |
7-9 | (A4C4)3CACA(G4T4)3G4 |
10-12 | A2C4(A4C4)2CACA(G4T4)3G4 |
13-15 | C4(A4C4)2CACA(G4T4)3 |
16-18 | (A4C4)3CACA(G4T4)3 |
19-21 | A2C4(A4C4)2CACA(G4T4)3 |
22-24 | C4(A4C4)2CACA(G4T4)3 |
25-27 | C2(A4C4)2CACA(G4T4)3 |
28-30 | (A4C4)2CACA(G4T4)3 |
引物 | 序列 |
TCP1.1 | GTGAAGGCACTGTTCAGCG |
TCP1.2 | GTGGATGATTTCTTGTTGG |
TCP1.3 | ATGCTCCTGCGTTTGGTGG |
TCP1.4 | CTGGACACTCAGCCCTTGG |
TCP1.5 | GGCAGGTGTGCTGGACACT |
TCP1.6 | TTTGATGATGCTGGCGATG |
TCP1.7 | GGGGCTCGTCTTCTACAGG |
TCP1.8 | CAGCAGGAGGATCTTGTAG |
TCP1.9 | TGACCCCAGGAGTGGCACG |
TCP1.10 | TCAAGCTGACTCGACACCG |
TCP1.11 | CGGCGTGACAGGGCTGC |
TCP1.12 | GCTGAAGGCTGAGTGTCC |
TCP1.13 | TAGTCCATGTTCACAATCG |
片段 | 引物组1 | 引物组2 | 最后大小 | 用于seq的引物 |
OA | na | K320/K322 | 208 | K320,K322 |
A | K320/TCP1.43 | TCP1.40/TCP1.34 | 556 | TCP1.52,TCP1.39,K322,TCP1.40,TCP1.41,TCP1.30,TCP1.34,TCP1.49 |
B | TCP1.42/TCP1.32B | TCP1.35/TCP1.21 | 492 | TCP1.35,TCP1.28,TCP1.38,TCP1.21,TCP1.46,TCP1.33,TCP1.48 |
C | TCP1.65/TCP1.66 | TCP1.67/TCP1.68 | 818 | TCP1.67,TCP1.32,TCP1.69,TCP1.68,TCP1.24,TCP1.44,K303 |
D2 | K304/billTCP6 | LT1/TCP1.6 | 546 | LT2,LT1,TCP1.6,bTCP4,TCP1.13,TCP1.77,TCP1.1 |
D3 | TCP1.12/TCP1.7 | TCP1.14/TCP1.15 | 604 | TCP1.6,TCP1.14,TCP1.73,TCP1.78,TCP1.25,TCP1.15,TCP1.76 |
EF | na | TCP1.74/TCP1.7 | 201 | TCP1.74,TCP1.7,TCP1.75,TCP1.15,TCP1.3 |
E | TCP1.3/TCP1.4 | TCP1.2/TCP1.9 | 687 | TCP1.2,TCP1.8,TCP1.9,TCP1.26 |
F | TCP1.26/UTR2 | TCP1.10/TCP1.4 | 377 | TCP1.4,TCP1.10,TCP1.11 |
Claims (145)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN971802564A CN1291231B (zh) | 1996-10-01 | 1997-10-01 | 人类的端粒酶催化亚单位 |
CN201010150493.9A CN102021153B (zh) | 1996-10-01 | 1997-10-01 | 人类的端粒酶催化亚单位 |
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72464396A | 1996-10-01 | 1996-10-01 | |
US08/724,643 | 1996-10-01 | ||
US84441997A | 1997-04-18 | 1997-04-18 | |
US08/844,419 | 1997-04-18 | ||
US84601797A | 1997-04-25 | 1997-04-25 | |
US08/846,017 | 1997-04-25 | ||
US08/851,843 US6093809A (en) | 1996-10-01 | 1997-05-06 | Telomerase |
US08/851,843 | 1997-05-06 | ||
US08/854,050 | 1997-05-09 | ||
US08/854,050 US6261836B1 (en) | 1996-10-01 | 1997-05-09 | Telomerase |
US91131297A | 1997-08-14 | 1997-08-14 | |
US91550397A | 1997-08-14 | 1997-08-14 | |
US08/912,951 US6475789B1 (en) | 1996-10-01 | 1997-08-14 | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US08/911,312 | 1997-08-14 | ||
US08/912,951 | 1997-08-14 | ||
US08/915,503 | 1997-08-14 | ||
CN971802564A CN1291231B (zh) | 1996-10-01 | 1997-10-01 | 人类的端粒酶催化亚单位 |
PCT/US1997/017885 WO1998014593A2 (en) | 1996-10-01 | 1997-10-01 | Human telomerase catalytic subunit |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010150493.9A Division CN102021153B (zh) | 1996-10-01 | 1997-10-01 | 人类的端粒酶催化亚单位 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1291231A true CN1291231A (zh) | 2001-04-11 |
CN1291231B CN1291231B (zh) | 2010-06-02 |
Family
ID=27575511
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97199534A Pending CN1254376A (zh) | 1996-10-01 | 1997-10-01 | 端粒酶逆转录酶 |
CN971802564A Expired - Lifetime CN1291231B (zh) | 1996-10-01 | 1997-10-01 | 人类的端粒酶催化亚单位 |
CN201010150493.9A Expired - Lifetime CN102021153B (zh) | 1996-10-01 | 1997-10-01 | 人类的端粒酶催化亚单位 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97199534A Pending CN1254376A (zh) | 1996-10-01 | 1997-10-01 | 端粒酶逆转录酶 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010150493.9A Expired - Lifetime CN102021153B (zh) | 1996-10-01 | 1997-10-01 | 人类的端粒酶催化亚单位 |
Country Status (21)
Country | Link |
---|---|
US (4) | US6166178A (zh) |
EP (6) | EP1783139B8 (zh) |
JP (7) | JP3869092B2 (zh) |
KR (2) | KR100530483B1 (zh) |
CN (3) | CN1254376A (zh) |
AT (3) | ATE449851T1 (zh) |
AU (2) | AU4803697A (zh) |
BR (3) | BRPI9712254B1 (zh) |
CA (3) | CA2267664C (zh) |
DE (5) | DE841396T1 (zh) |
EA (2) | EA199900349A1 (zh) |
ES (1) | ES2205132T5 (zh) |
FI (1) | FI990655A0 (zh) |
FR (1) | FR2757177A1 (zh) |
GB (2) | GB2317891C (zh) |
HK (1) | HK1156967A1 (zh) |
IL (2) | IL129103A0 (zh) |
NO (2) | NO319982B1 (zh) |
NZ (1) | NZ334709A (zh) |
SG (1) | SG94355A1 (zh) |
WO (2) | WO1998014592A2 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104507489A (zh) * | 2012-05-11 | 2015-04-08 | 凯尔杰姆维克斯有限公司 | 用于预防和治疗类风湿性关节炎的组合物 |
CN104507961A (zh) * | 2012-05-11 | 2015-04-08 | 凯尔杰姆维克斯有限公司 | 抗炎性肽及包含其的组合物 |
CN105132439A (zh) * | 2006-07-28 | 2015-12-09 | 宾夕法尼亚大学托管会 | 改进的疫苗及其使用方法 |
CN109545039A (zh) * | 2019-01-15 | 2019-03-29 | 苏州大学 | 一种核孔复合体结构模型教具及其使用方法 |
CN112063601A (zh) * | 2020-09-22 | 2020-12-11 | 上海慧灯医疗科技有限公司 | 一种灭活性端粒酶、具有其的腺病毒和人造mRNA及应用 |
CN114920802A (zh) * | 2022-05-16 | 2022-08-19 | 中国地质大学(武汉) | 调节端粒酶限速蛋白运动的多肽探针及其复合物和方法 |
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US6517834B1 (en) | 1995-08-04 | 2003-02-11 | Geron Corporation | Purified telomerase |
US6545133B1 (en) | 1995-08-04 | 2003-04-08 | Geron Corporation | Methods for purifying telomerase |
AU1867397A (en) | 1995-11-16 | 1997-06-05 | Michael W. Dahm | Method of quantifying tumour cells in a body fluid and a suitable test kit |
US6881571B1 (en) * | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
US6607898B1 (en) * | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6808880B2 (en) | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
US6444650B1 (en) * | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
JP3869092B2 (ja) * | 1996-10-01 | 2007-01-17 | ジェロン・コーポレーション | ヒトテロメラーゼ触媒性サブユニット |
US6777203B1 (en) | 1997-11-19 | 2004-08-17 | Geron Corporation | Telomerase promoter driving expression of therapeutic gene sequences |
US7390891B1 (en) | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
EP0942991A2 (en) * | 1996-11-26 | 1999-09-22 | Baylor College Of Medicine | Identification of inhibitors that prevent access of telomerase to chromosomal terminus |
WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
US20050013825A1 (en) * | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
EP0990037A2 (de) * | 1997-06-20 | 2000-04-05 | Bayer Ag | Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung |
EP1571215A3 (en) * | 1997-07-01 | 2007-10-31 | Cambia Biosystems LLC | Vertebrate telomerase genes and proteins and uses thereof |
CN1270634A (zh) * | 1997-07-01 | 2000-10-18 | 卡姆比亚生物系统有限责任公司 | 脊椎动物端粒酶基因和蛋白质及其用途 |
US7378244B2 (en) | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
WO1999027113A1 (en) * | 1997-11-26 | 1999-06-03 | Geron Corporation | Mouse telomerase reverse transcriptase |
DE19757984A1 (de) * | 1997-12-24 | 1999-07-01 | Bayer Ag | Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung |
DE19804372A1 (de) * | 1998-02-04 | 1999-08-05 | Michael W Dr Dr Dahm | Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits |
CA2291798A1 (en) * | 1998-03-26 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Monoclonal antibody against human telomerase catalytic subunit |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
WO1999050392A1 (en) | 1998-03-31 | 1999-10-07 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
US20030105315A1 (en) * | 1998-04-09 | 2003-06-05 | Metagen Pharmaceuticals Gmbh | Human nucleic acid sequences from ovarian tumor tissue |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
EP1126872B1 (en) | 1998-10-29 | 2006-12-13 | Dana-Farber Cancer Institute, Inc. | CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT |
GB9900298D0 (en) * | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
WO2000043501A2 (de) * | 1999-01-22 | 2000-07-27 | Humboldt-Universität Zu Berlin Universitätsklinikum Charite | GEGEN DIE KATALYTISCHE UNTEREINHEIT DER HUMANEN TELOMERASE (hTERT) GERICHTETE RIBOZYME |
AU761567B2 (en) * | 1999-02-04 | 2003-06-05 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
DE60036700T2 (de) | 1999-04-08 | 2008-07-24 | Antisoma Research Ltd. | Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
JP2002541811A (ja) * | 1999-04-09 | 2002-12-10 | バイオミラ,インコーポレイテッド | テロメラーゼ特異的癌ワクチン |
US6358739B1 (en) * | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
DE19916929A1 (de) * | 1999-04-15 | 2000-10-19 | Bayer Ag | Ein automatisierbarer Schnelltest zum Nachweis von Krebserkrankungen auf der Basis von Telomerase(hTC) mRNA mit spezifischen Primern und Sonden |
US6995145B1 (en) | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
US20050255596A1 (en) * | 1999-09-07 | 2005-11-17 | West Michael D | Methods of repairing tandemly repeated DNA sequences and extending cell life-span nuclear transfer |
AU767646B2 (en) | 1999-09-10 | 2003-11-20 | Geron Corporation | Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use |
FR2798673B1 (fr) * | 1999-09-16 | 2004-05-28 | Exonhit Therapeutics Sa | Methodes et compositions pour la detection d'evenements pathologiques |
US6399384B1 (en) | 1999-09-17 | 2002-06-04 | Reneuron Limited | Conditional immortalization of cells |
AU1309101A (en) * | 1999-11-16 | 2001-05-30 | Kyowa Hakko Kogyo Co. Ltd. | Method of searching for substance inhibiting binding between telomerase subunits |
GB9927353D0 (en) * | 1999-11-19 | 2000-01-19 | Cantab Pharma Res | Virus preparation and use |
US6664046B1 (en) * | 1999-12-16 | 2003-12-16 | Roche Molecular Systems, Inc. | Quantitation of hTERT mRNA expression |
KR20010096991A (ko) * | 2000-04-19 | 2001-11-08 | 임정빈 | 텔로머레이즈의 프로모터에 특정하게 결합하는더블유티이1 절편, 그 유전자, 발현벡터 및 그것을 이용한세포성장 억제 방법 |
US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
IT1318504B1 (it) * | 2000-05-08 | 2003-08-27 | Talent Srl | Metodo e apparecchiatura per la diagnosi precoce di tumori vescicalisu campioni di urina. |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
US6492171B2 (en) * | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
EP1158055A1 (fr) | 2000-05-26 | 2001-11-28 | Xu Qi University of Teaxs Laboratoire de Leucémie Chen | Méthode pour le diagnostic de cancers |
US7078491B1 (en) | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
WO2002048319A1 (en) * | 2000-12-14 | 2002-06-20 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Telomerase immortalized human liver cell lines |
US6906237B2 (en) * | 2001-02-27 | 2005-06-14 | G. Scott Herron | Vivo assay for anti angiogenic compounds |
US20040063922A1 (en) * | 2001-04-17 | 2004-04-01 | Conrad Charles A. | Methods and compositions for catalytic DNA exchange in a sequence specific manner |
WO2002091999A2 (en) * | 2001-05-09 | 2002-11-21 | Geron Corporation | Treatment for wounds |
GB0112342D0 (en) * | 2001-05-21 | 2001-07-11 | Norsk Hydro As | Polypeptides |
ATE400649T1 (de) | 2001-07-16 | 2008-07-15 | Fuyuki Ishikawa | Neues verfahren zur induktion von zellulären seneszenz und screening-verfahren für ein mittel gegen alterung |
US7150989B2 (en) * | 2001-08-10 | 2006-12-19 | Cornell Research Foundation, Inc. | Telomerase immortalized neural progenitor cells |
AUPR769701A0 (en) * | 2001-09-14 | 2001-10-11 | Li, He | Telomerase inhibitory peptides and uses thereof |
DE50214367D1 (de) * | 2001-10-18 | 2010-05-27 | Heart Biosystems Gmbh | Transiente immortalisierung von zellen durch onkogenproteine oder telomerproteine |
CA2478681A1 (en) * | 2001-10-22 | 2003-05-01 | University Of Rochester | Telomerase interference |
US20050084959A1 (en) * | 2001-10-31 | 2005-04-21 | Hirofumi Hamada | Immortalized mesenchymal cells and utilization thereof |
JP5364224B2 (ja) | 2001-12-07 | 2013-12-11 | ジェロン・コーポレーション | ヒト胚性幹細胞に由来する造血細胞 |
EP2264146A1 (en) | 2001-12-07 | 2010-12-22 | Geron Corporation | Islet cells from human embryonic stem cells |
DE10163130B4 (de) * | 2001-12-20 | 2009-05-14 | Cyto Tools Gmbh | Apoptotisch wirksame Peptide und diese umfassende pharmazeutische Zusammensetzungen |
AU2002357613A1 (en) * | 2001-12-21 | 2003-07-09 | Shuichi Kaneko | Method of detecting antitelomerase antibody |
GB0200929D0 (en) * | 2002-01-16 | 2002-03-06 | Univ Glasgow | Tissue rejection |
CA2473741C (en) * | 2002-01-18 | 2015-12-22 | Morphotek, Inc. | A method for generating engineered cells for locus specific gene regulation and analysis |
US20030175961A1 (en) * | 2002-02-26 | 2003-09-18 | Herron G. Scott | Immortal micorvascular endothelial cells and uses thereof |
US20050106729A1 (en) * | 2002-05-03 | 2005-05-19 | Mark Irvin Rosenblatt | Gene transfer methods and compositions |
WO2003100025A2 (en) * | 2002-05-28 | 2003-12-04 | Regents Of The University Of Minnesota | Crisp polypeptides as contraceptives and inhibitors of sperm capacitation |
US7294708B2 (en) * | 2002-05-31 | 2007-11-13 | Beijing Institute Of Biotechnology | Telomerase reverse transcriptase fragments and uses thereof |
JP2005535310A (ja) * | 2002-06-18 | 2005-11-24 | ザイモジェネティクス,インコーポレイティド | サイトメガロウィルスエンハンサー及び骨髄増殖性肉腫ウィルスプロモーターを有するハイブリッドベクター |
US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
CA2502490A1 (en) | 2002-11-08 | 2004-05-27 | Hematech, Llc | Transgenic ungulates having reduced prion protein activity and uses thereof |
US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
WO2004099385A2 (en) * | 2003-04-30 | 2004-11-18 | Duke University | Telomere elongation |
WO2005000245A2 (en) | 2003-06-23 | 2005-01-06 | Geron Corporation | Compositions and methods for increasing telomerase activity |
JP4423428B2 (ja) * | 2003-09-12 | 2010-03-03 | リニューロン・リミテッド | 細胞療法 |
EP1522858A1 (en) * | 2003-10-10 | 2005-04-13 | Jean-Christophe Roegel | Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
JP2007533328A (ja) | 2004-04-22 | 2007-11-22 | キリンホールディングス株式会社 | トランスジェニック動物及びその用途 |
WO2005108598A1 (en) | 2004-05-11 | 2005-11-17 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
AU2005285483A1 (en) * | 2004-08-05 | 2006-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for cell activation |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
JP2006242618A (ja) * | 2005-03-01 | 2006-09-14 | Univ Of Tokyo | 組織fish法によるテロメア量を指標とした癌の診断 |
JP4635196B2 (ja) * | 2005-03-04 | 2011-02-16 | 国立大学法人広島大学 | 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法 |
AU2006220500A1 (en) * | 2005-03-09 | 2006-09-14 | Board Of Regents, The University Of Texas System | Novel hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes |
EP1886138A4 (en) * | 2005-05-11 | 2009-04-15 | Genetic Technologies Ltd | PROCESS FOR ENRICHING FETTAL CELLS |
EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
CN103989710B (zh) | 2005-12-21 | 2019-11-15 | 鲁汶大学 | 分离的肝脏干细胞 |
US8415153B2 (en) | 2006-06-19 | 2013-04-09 | Geron Corporation | Differentiation and enrichment of islet-like cells from human pluripotent stem cells |
WO2008002285A1 (en) * | 2006-06-26 | 2008-01-03 | Science Applications International Corporation | Igy antibodies to human telomerase reverse transcriptase |
US20080131442A1 (en) * | 2006-06-26 | 2008-06-05 | Science Applications International Corporation | IgY antibodies to human telomerase reverse transcriptase |
AU2013203229C1 (en) * | 2006-07-28 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
CN101522706B (zh) * | 2006-10-12 | 2013-09-04 | P.安杰莱蒂分子生物学研究所 | 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途 |
SI3255061T1 (sl) | 2006-11-03 | 2021-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev |
EP1994942A1 (en) * | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
CA2781407A1 (en) | 2008-01-14 | 2009-07-23 | Michael P. Brenzel | Apparatus and methods for fracture repair |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
AU2010239131A1 (en) | 2009-04-21 | 2011-11-17 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
CA2767825A1 (en) * | 2009-07-09 | 2011-01-13 | Janssen Biotech, Inc. | Cardiac tissue-derived cells |
WO2011088172A1 (en) | 2010-01-15 | 2011-07-21 | Brenzel Michael P | Rotary-rigid orthopaedic rod |
CN102821707B (zh) | 2010-01-20 | 2016-02-03 | 康文图斯整形外科公司 | 用于骨接近和骨腔准备的装置及方法 |
JP6042211B2 (ja) | 2010-02-16 | 2016-12-14 | ウルティモバックス エーエス | ポリペプチド |
WO2011106671A1 (en) * | 2010-02-26 | 2011-09-01 | Geron Corporation | Assay for telomerase activity |
CN105361942B (zh) | 2010-03-08 | 2018-01-09 | 康文图斯整形外科公司 | 用于固定骨植入物的装置及方法 |
EP2556147B1 (en) | 2010-04-08 | 2018-10-03 | The University Court Of The University of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
JPWO2012026309A1 (ja) * | 2010-08-23 | 2013-10-28 | 公立大学法人横浜市立大学 | 抗pad4抗体医薬の創成 |
CN102093980B (zh) * | 2010-12-10 | 2013-04-17 | 梁伟国 | 永生化人椎间盘髓核细胞体系的制备方法 |
US8420617B2 (en) * | 2011-03-11 | 2013-04-16 | Biocell Laboratories | Multiantivirus compound, composition and method for treatment of virus diseases |
CN102676518B (zh) * | 2012-02-27 | 2013-09-18 | 华侨大学 | 一种新型抗肿瘤amiRNA序列及其应用 |
EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
BR112014032677A2 (pt) * | 2012-06-27 | 2019-01-15 | Univ Rutgers | ensaios rápido para ativação de célula t por medições de rna usando citometria de fluxo |
US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
TWI598441B (zh) * | 2012-09-19 | 2017-09-11 | 傑姆維克斯&凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物(四) |
US9902945B2 (en) * | 2012-09-19 | 2018-02-27 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
KR102166542B1 (ko) | 2012-09-28 | 2020-10-16 | 주식회사 젬백스앤카엘 | 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제 |
KR102106756B1 (ko) | 2012-12-13 | 2020-05-06 | 주식회사 젬백스앤카엘 | 자외선에 의한 피부 손상 예방 또는 치료용 조성물 |
KR102093093B1 (ko) | 2012-12-13 | 2020-03-25 | 주식회사 젬백스앤카엘 | 피부 노화 개선용 조성물 |
HUE056638T2 (hu) | 2013-02-22 | 2022-02-28 | Univ Leland Stanford Junior | Telomer kiterjesztéssel kapcsolatos gyógyászati alkalmazás |
EP3449936A1 (en) | 2013-03-28 | 2019-03-06 | Invectys | A cancer vaccine for cats |
DK2978444T3 (en) | 2013-03-28 | 2019-03-18 | Invectys | CANCERVACCINE FOR DOGS |
DE202014011287U1 (de) | 2013-06-11 | 2019-02-06 | The President And Fellows Of Harvard College | SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen |
BR112016008807B1 (pt) | 2013-10-28 | 2021-07-06 | Invectys | uso de um ácido nucleico |
RS60232B1 (sr) | 2013-10-28 | 2020-06-30 | Invectys | Dnk vakcina za kodiranje telomeraze |
EP2871235A1 (en) | 2013-11-07 | 2015-05-13 | Centre National de la Recherche Scientifique (CNRS) | New methods to produce active hTERT |
WO2015089357A2 (en) | 2013-12-12 | 2015-06-18 | Conventus Orthopaedics, Inc. | Tissue displacement tools and methods |
KR102166549B1 (ko) | 2014-01-10 | 2020-10-16 | 주식회사 젬백스앤카엘 | 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
PL3656869T3 (pl) | 2014-08-26 | 2021-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Wszczepienie komórek macierzystych z kombinacją środka, który celuje w komórki macierzyste i modulowanie sygnałowania immunoregulatorowego |
US20190209697A1 (en) | 2015-11-05 | 2019-07-11 | The Regents Of The University Of California | Cells labelled with lipid conjugates and methods of use thereof |
HUE051722T2 (hu) | 2016-01-19 | 2021-03-29 | Pfizer | Rák elleni oltóanyagok |
AU2018213397A1 (en) | 2017-01-30 | 2019-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | A non-genotoxic conditioning regimen for stem cell transplantation |
US10631881B2 (en) | 2017-03-09 | 2020-04-28 | Flower Orthopedics Corporation | Plating depth gauge and countersink instrument |
EP3622078A1 (en) | 2017-05-09 | 2020-03-18 | Invectys | Recombinant measles vaccine expressing htert |
WO2019010252A2 (en) | 2017-07-04 | 2019-01-10 | Conventus Orthopaedics, Inc. | APPARATUS AND METHODS FOR TREATING BONES |
EP3675878A4 (en) | 2017-10-02 | 2021-06-16 | Fred Hutchinson Cancer Research Center | LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS |
CN108715863B (zh) * | 2018-05-30 | 2020-09-11 | 吉林大学 | 一种肿瘤靶向性载体pcTERT及其构建方法及其应用 |
CN110827920B (zh) * | 2018-08-14 | 2022-11-22 | 武汉华大医学检验所有限公司 | 测序数据分析方法和设备及高通量测序方法 |
EP3847274A4 (en) * | 2018-09-05 | 2022-06-08 | Readcoor, LLC | METHODS AND SYSTEMS FOR THERAPEUTIC AGENT ANALYSIS |
CA3109063A1 (en) * | 2018-09-06 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Telomerase holoenzyme complex and methods of use thereof |
JP2022539249A (ja) | 2019-07-05 | 2022-09-07 | ケース ウェスタン リザーブ ユニバーシティ | 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法 |
JP2021151979A (ja) * | 2020-03-24 | 2021-09-30 | 均 石井 | 再生医療薬 |
JP2022151412A (ja) * | 2021-03-23 | 2022-10-07 | 均 石井 | 脳卒中治療薬 |
CN113355303B (zh) * | 2021-06-07 | 2023-06-16 | 中元汇吉生物技术股份有限公司 | 一种m-mlv逆转录酶突变体及其应用 |
WO2023141534A1 (en) * | 2022-01-19 | 2023-07-27 | Northwestern University | Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy |
CN116364195B (zh) * | 2023-05-10 | 2023-10-13 | 浙大城市学院 | 一种基于预训练模型的微生物遗传序列表型预测方法 |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US912629A (en) | 1908-08-29 | 1909-02-16 | Conrad L Stueber | Foundation-top for pipe-carriers. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4254082A (en) | 1978-06-12 | 1981-03-03 | Miles Laboratories, Inc. | Specific binding-adsorbent assay test means |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
JPS57502090A (zh) | 1980-07-18 | 1982-11-25 | ||
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
US5055556A (en) | 1981-10-06 | 1991-10-08 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Fluorescent conjugates for analysis of molecules and cells |
JPS58215453A (ja) | 1982-06-09 | 1983-12-14 | Toray Silicone Co Ltd | 室温硬化後塗装可能なオルガノポリシロキサン組成物 |
FR2542494B1 (fr) | 1983-03-08 | 1985-08-16 | Sevylor International | Combinaison protectrice, utilisable notamment en atmosphere irradiee |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5272065A (en) | 1983-10-20 | 1993-12-21 | Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
GB8612087D0 (en) | 1986-05-19 | 1986-06-25 | Ici Plc | Hybridisation probes |
US5001225A (en) | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
US4889806A (en) | 1987-04-15 | 1989-12-26 | Washington University | Large DNA cloning system based on yeast artificial chromosomes |
US5017478A (en) | 1987-07-16 | 1991-05-21 | Berlex Laboratories, Inc. | Transfected cells containing plasmids having genes oriented in opposing directions and methods of using |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5093245A (en) | 1988-01-26 | 1992-03-03 | Applied Biosystems | Labeling by simultaneous ligation and restriction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5075227A (en) * | 1989-03-07 | 1991-12-24 | Zymogenetics, Inc. | Directional cloning |
JPH02307059A (ja) | 1989-05-23 | 1990-12-20 | Seiko Instr Inc | 反応容器 |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5437994A (en) | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
DK0502976T3 (da) | 1989-12-01 | 1996-11-11 | Pharming Bv | Produktion af rekombinante polypeptider ved bovine arter og transgene fremgangsmåder |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
EP0779362B2 (en) | 1989-12-22 | 2012-06-13 | Laboratoires Serono SA | DNA constructs for endogenous gene activation and expression modification |
JPH04505546A (ja) | 1990-02-09 | 1992-09-24 | アスラブ ソシエテ アノニム | 写真平版マイクロ製造法を用いて製造した放射場静電マイクロモーター及び前記マイクロモーターの製造方法 |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
SE468913B (sv) | 1990-05-16 | 1993-04-05 | Igesto Ab | Saekerhetskrok |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
KR100198659B1 (ko) | 1996-05-16 | 1999-06-15 | 구본준 | 메모리 셀, 메모리 장치 및 그의 제조 방법 |
JP2904583B2 (ja) | 1991-10-11 | 1999-06-14 | プロメガ・コーポレーション | 真核無細胞抽出物中での転写と翻訳の共役 |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
JPH08500481A (ja) | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ウイルスの複製を阻害するための方法および薬剤 |
US5645986A (en) | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5639613A (en) | 1992-05-13 | 1997-06-17 | Board Of Regents, University Of Texas System | Methods for cancer diagnosis and prognosis |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US5648215A (en) | 1992-05-13 | 1997-07-15 | Board Of Regents, The University Of Texas System | Telomerase diagnostic methods |
EP1251170A3 (en) | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of NF-kappaB dependent animal diseases |
US6107062A (en) | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
GB2273932A (en) | 1992-11-24 | 1994-07-06 | Stiefel Laboratories | Stable oligonucleotides |
US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
EP0686200A4 (en) | 1993-01-27 | 1997-07-02 | Oncor Inc | AMPLIFICATION OF NUCLEIC ACID SEQUENCES |
US6140087A (en) | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
US6120764A (en) | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
WO1995013382A1 (en) * | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
EP0778842B1 (en) | 1994-07-07 | 2005-11-02 | Geron Corporation | Mammalian telomerase |
US5597697A (en) | 1994-09-30 | 1997-01-28 | Diamond; Paul | Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases |
US5698686A (en) * | 1994-10-20 | 1997-12-16 | Arch Development Corporation | Yeast telomerase compositions |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
JPH10513343A (ja) * | 1994-12-19 | 1998-12-22 | コールド スプリング ハーバー ラボラトリー | テロメラーゼの蛋白質成分 |
US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
JPH11507818A (ja) | 1995-06-07 | 1999-07-13 | コールド・スプリング・ハーバー・ラボラトリー | 脊椎動物テロメラーゼの必須オリゴヌクレオチド |
US5722998A (en) | 1995-06-07 | 1998-03-03 | Intermedics, Inc. | Apparatus and method for the control of an implantable medical device |
WO1997015687A1 (en) | 1995-06-07 | 1997-05-01 | Geron Corporation | Telomerase activity assays |
US6517834B1 (en) | 1995-08-04 | 2003-02-11 | Geron Corporation | Purified telomerase |
JP3372258B2 (ja) | 1995-08-04 | 2003-01-27 | インターナシヨナル・ビジネス・マシーンズ・コーポレーシヨン | リソグラフィ・プロセス用のスタンプ |
US5968506A (en) | 1995-08-04 | 1999-10-19 | Geron Corporation | Purified telomerase |
US6545133B1 (en) | 1995-08-04 | 2003-04-08 | Geron Corporation | Methods for purifying telomerase |
JPH09154575A (ja) | 1995-10-04 | 1997-06-17 | Soosei:Kk | テロメラーゼ |
JPH09164575A (ja) | 1995-12-13 | 1997-06-24 | Japan Steel Works Ltd:The | 流れ模様を有する樹脂板の製造方法およびその装置 |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
US5747317A (en) | 1996-07-08 | 1998-05-05 | Tularik Inc. | Human telomerase RNA interacting protein gene |
US5770422A (en) | 1996-07-08 | 1998-06-23 | The Regents Of The University Of California | Human telomerase |
US5724021A (en) | 1996-07-09 | 1998-03-03 | Stephen C. Perrone | Self-contained, programmable, time interval alarm reminder device for eyedrop medication administration and a means for affixing such to eyedrop/medication container |
WO1998007838A1 (fr) | 1996-08-21 | 1998-02-26 | Mitsubishi Chemical Corporation | Proteine de telomerase d'animaux superieurs et gene codant pour elle |
WO1998008938A1 (en) | 1996-08-28 | 1998-03-05 | Shonen Yoshida | Proteins having telomerase activity |
DE19638482A1 (de) | 1996-09-20 | 1998-04-02 | Bosch Gmbh Robert | Verfahren zur Auswahl einer Sendefrequenz |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
US6767719B1 (en) | 1997-11-26 | 2004-07-27 | Geron Corporation | Mouse telomerase reverse transcriptase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
US6808880B2 (en) | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
US6777203B1 (en) | 1997-11-19 | 2004-08-17 | Geron Corporation | Telomerase promoter driving expression of therapeutic gene sequences |
JP3869092B2 (ja) | 1996-10-01 | 2007-01-17 | ジェロン・コーポレーション | ヒトテロメラーゼ触媒性サブユニット |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US5890326A (en) | 1996-11-06 | 1999-04-06 | Hill-Rom, Inc. | Head wall for a hospital room |
US7390891B1 (en) | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
US5919656A (en) | 1996-11-15 | 1999-07-06 | Amgen Canada Inc. | Genes encoding telomerase protein 1 |
EP0942991A2 (en) | 1996-11-26 | 1999-09-22 | Baylor College Of Medicine | Identification of inhibitors that prevent access of telomerase to chromosomal terminus |
WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
US6617119B2 (en) | 1997-02-21 | 2003-09-09 | The Regents Of The University Of California | Assay for specific strains of multiple disease related conformations of a protein |
ATE250130T1 (de) * | 1997-04-04 | 2003-10-15 | Geron Corp | Gereinigte telomerase |
US6485789B1 (en) | 1997-04-14 | 2002-11-26 | 3M Innovative Properties Company | Fluorochemical composition containing a condensation product of a fluorochemical polyether and a poly-isocyanate to impart stain release properties to a substrate |
US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
US20050013825A1 (en) | 1997-04-18 | 2005-01-20 | Geron Corporation | Vaccine containing the catalytic subunit of telomerase for treating cancer |
US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US6201830B1 (en) | 1997-06-11 | 2001-03-13 | Texas Instruments Incorporated | Low computation idle transmission method for DSL modems |
EP0990037A2 (de) * | 1997-06-20 | 2000-04-05 | Bayer Ag | Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung |
CN1270634A (zh) | 1997-07-01 | 2000-10-18 | 卡姆比亚生物系统有限责任公司 | 脊椎动物端粒酶基因和蛋白质及其用途 |
US7378244B2 (en) | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
WO1999027113A1 (en) | 1997-11-26 | 1999-06-03 | Geron Corporation | Mouse telomerase reverse transcriptase |
DE19757984A1 (de) | 1997-12-24 | 1999-07-01 | Bayer Ag | Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung |
ATE328079T1 (de) | 1998-01-08 | 2006-06-15 | Chugai Pharmaceutical Co Ltd | Neues gen mit einem revers-transkriptase-motiv |
GB9801902D0 (en) | 1998-01-29 | 1998-03-25 | Cancer Res Campaign Tech | A gene promoter |
WO1999050392A1 (en) | 1998-03-31 | 1999-10-07 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
CA2331378A1 (en) | 1998-06-12 | 1999-12-16 | Sloan-Kettering Institute For Cancer Research | Vaccination strategy to prevent and treat cancers |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
AU761567B2 (en) | 1999-02-04 | 2003-06-05 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
JP2002541811A (ja) | 1999-04-09 | 2002-12-10 | バイオミラ,インコーポレイテッド | テロメラーゼ特異的癌ワクチン |
WO2000073420A2 (en) | 1999-06-02 | 2000-12-07 | Whitehead Institute For Biomedical Research | Creation of human tumorigenic cells and uses therefor |
US6354941B2 (en) | 1999-11-03 | 2002-03-12 | 516 Holdings | Electronic system for a game of chance |
AU2001241533A1 (en) | 2000-02-15 | 2001-08-27 | The Regents Of The University Of California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
WO2002091999A2 (en) | 2001-05-09 | 2002-11-21 | Geron Corporation | Treatment for wounds |
JP2002348474A (ja) | 2001-05-23 | 2002-12-04 | Dow Corning Toray Silicone Co Ltd | ポリオルガノシロキサンマイクロエマルジョン組成物および化粧料原料 |
WO2003038047A2 (en) | 2001-10-29 | 2003-05-08 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
US7294708B2 (en) | 2002-05-31 | 2007-11-13 | Beijing Institute Of Biotechnology | Telomerase reverse transcriptase fragments and uses thereof |
KR100705868B1 (ko) | 2003-05-06 | 2007-04-10 | 후지 덴키 디바이스 테크놀로지 가부시키가이샤 | 반도체 장치 및 그 제조 방법 |
-
1997
- 1997-10-01 JP JP28618297A patent/JP3869092B2/ja not_active Expired - Lifetime
- 1997-10-01 BR BRPI9712254A patent/BRPI9712254B1/pt unknown
- 1997-10-01 CA CA2267664A patent/CA2267664C/en not_active Expired - Lifetime
- 1997-10-01 NZ NZ334709A patent/NZ334709A/en not_active IP Right Cessation
- 1997-10-01 IL IL12910397A patent/IL129103A0/xx not_active IP Right Cessation
- 1997-10-01 DE DE0841396T patent/DE841396T1/de active Pending
- 1997-10-01 EP EP06117664A patent/EP1783139B8/en not_active Expired - Lifetime
- 1997-10-01 AT AT97910785T patent/ATE449851T1/de not_active IP Right Cessation
- 1997-10-01 AT AT97307757T patent/ATE245194T1/de active
- 1997-10-01 DE DE69739497T patent/DE69739497D1/de not_active Expired - Lifetime
- 1997-10-01 JP JP51690998A patent/JP2001510985A/ja active Pending
- 1997-10-01 GB GB9720890.4A patent/GB2317891C/en not_active Expired - Lifetime
- 1997-10-01 BR BR9712254-8A patent/BR9712254A/pt not_active IP Right Cessation
- 1997-10-01 IL IL12922297A patent/IL129222A0/xx unknown
- 1997-10-01 DE DE69739675T patent/DE69739675D1/de not_active Expired - Lifetime
- 1997-10-01 EP EP20090176870 patent/EP2213740A1/en not_active Withdrawn
- 1997-10-01 CN CN97199534A patent/CN1254376A/zh active Pending
- 1997-10-01 CN CN971802564A patent/CN1291231B/zh not_active Expired - Lifetime
- 1997-10-01 EP EP03075454A patent/EP1333094B1/en not_active Expired - Lifetime
- 1997-10-01 DE DE19743497A patent/DE19743497A1/de not_active Withdrawn
- 1997-10-01 CA CA002266752A patent/CA2266752A1/en not_active Abandoned
- 1997-10-01 EP EP97307757A patent/EP0841396B2/en not_active Expired - Lifetime
- 1997-10-01 KR KR1019997002838A patent/KR100530483B1/ko not_active IP Right Cessation
- 1997-10-01 KR KR1019990702815A patent/KR20000048820A/ko not_active Application Discontinuation
- 1997-10-01 ES ES97307757T patent/ES2205132T5/es not_active Expired - Lifetime
- 1997-10-01 AU AU48036/97A patent/AU4803697A/en not_active Abandoned
- 1997-10-01 JP JP51680298A patent/JP2001523947A/ja active Pending
- 1997-10-01 GB GB9804859A patent/GB2321642B8/en not_active Expired - Lifetime
- 1997-10-01 SG SG200101834A patent/SG94355A1/en unknown
- 1997-10-01 WO PCT/US1997/017618 patent/WO1998014592A2/en not_active Application Discontinuation
- 1997-10-01 EA EA199900349A patent/EA199900349A1/ru unknown
- 1997-10-01 EA EA199900355A patent/EA199900355A1/ru unknown
- 1997-10-01 EP EP97910785A patent/EP0954585B1/en not_active Expired - Lifetime
- 1997-10-01 AU AU48073/97A patent/AU734089B2/en not_active Expired
- 1997-10-01 BR BR9711844-3A patent/BR9711844A/pt unknown
- 1997-10-01 WO PCT/US1997/017885 patent/WO1998014593A2/en not_active Application Discontinuation
- 1997-10-01 DE DE69723531T patent/DE69723531T3/de not_active Expired - Lifetime
- 1997-10-01 FR FR9712217A patent/FR2757177A1/fr active Pending
- 1997-10-01 CA CA2645721A patent/CA2645721C/en not_active Expired - Lifetime
- 1997-10-01 AT AT03075454T patent/ATE552341T1/de active
- 1997-10-01 EP EP97910737A patent/EP0932686A2/en not_active Withdrawn
- 1997-10-01 CN CN201010150493.9A patent/CN102021153B/zh not_active Expired - Lifetime
- 1997-11-19 US US08/974,549 patent/US6166178A/en not_active Expired - Lifetime
-
1998
- 1998-10-15 JP JP32016998A patent/JP4070331B2/ja not_active Expired - Lifetime
-
1999
- 1999-02-19 JP JP11042410A patent/JPH11313689A/ja active Pending
- 1999-03-24 FI FI990655A patent/FI990655A0/fi unknown
- 1999-03-31 NO NO19991588A patent/NO319982B1/no not_active IP Right Cessation
-
2000
- 2000-07-27 JP JP2000227474A patent/JP2001081042A/ja not_active Withdrawn
- 2000-11-22 US US09/721,477 patent/US7517971B1/en not_active Expired - Fee Related
- 2000-11-22 US US09/721,456 patent/US6617110B1/en not_active Expired - Lifetime
-
2005
- 2005-06-24 NO NO20053120A patent/NO332085B1/no unknown
-
2007
- 2007-08-20 US US11/894,600 patent/US8222392B2/en not_active Expired - Fee Related
-
2008
- 2008-07-28 JP JP2008194208A patent/JP4852576B2/ja not_active Expired - Lifetime
-
2011
- 2011-10-18 HK HK11111117.2A patent/HK1156967A1/zh not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105132439A (zh) * | 2006-07-28 | 2015-12-09 | 宾夕法尼亚大学托管会 | 改进的疫苗及其使用方法 |
CN104507489A (zh) * | 2012-05-11 | 2015-04-08 | 凯尔杰姆维克斯有限公司 | 用于预防和治疗类风湿性关节炎的组合物 |
CN104507961A (zh) * | 2012-05-11 | 2015-04-08 | 凯尔杰姆维克斯有限公司 | 抗炎性肽及包含其的组合物 |
CN104507489B (zh) * | 2012-05-11 | 2016-07-13 | 杰姆维克斯&凯尔有限公司 | 用于预防和治疗类风湿性关节炎的组合物 |
CN104507961B (zh) * | 2012-05-11 | 2018-08-14 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
CN109545039A (zh) * | 2019-01-15 | 2019-03-29 | 苏州大学 | 一种核孔复合体结构模型教具及其使用方法 |
CN112063601A (zh) * | 2020-09-22 | 2020-12-11 | 上海慧灯医疗科技有限公司 | 一种灭活性端粒酶、具有其的腺病毒和人造mRNA及应用 |
CN114920802A (zh) * | 2022-05-16 | 2022-08-19 | 中国地质大学(武汉) | 调节端粒酶限速蛋白运动的多肽探针及其复合物和方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1291231A (zh) | 人类的端粒酶催化亚单位 | |
US8236774B2 (en) | Human telomerase catalytic subunit | |
US6610839B1 (en) | Promoter for telomerase reverse transcriptase | |
US8709995B2 (en) | Method for eliciting an immune response to human telomerase reverse transcriptase | |
US7413864B2 (en) | Treating cancer using a telomerase vaccine | |
AU763956B2 (en) | Promoter for human telomerase reverse transcriptase | |
AU6551801A (en) | Human telomerase catalytic subunit | |
NZ510761A (en) | Human telomerase promoter and in vitro use is described |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090109 Address after: California, USA Applicant after: Geron Co-applicant after: Regents of The Univ. of Colorado Address before: California, USA Applicant before: Geron Co-applicant before: University licensing equity holding company |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 08/724,643;19961001;US|08/844,419;19970418;US|08/846,017;19970425;US|08/851,843;19970506;US|08/854,050;19970509;US|08/911,312;19970814;US|08/912,951;19970814;US|08/915,503;19970814;US False: 08/724,643 19961001 US Number: 22 Volume: 26 |
|
CI02 | Correction of invention patent application |
Correction item: Priority Correct: 08/724,643;19961001;US|08/844,419;19970418;US|08/846,017;19970425;US|08/851,843;19970506;US|08/854,050;19970509;US|08/911,312;19970814;US|08/912,951;19970814;US|08/915,503;19970814;USsand and one|US (2) 08/844419|Nineteen million nine hundred and seventy thousand four hundred and eighteen|US (3) 08/846017|Nineteen million nine hundred and seventy thousand four hundred and twenty-five|US (4) 08/851843|Nineteen million nine hundred and seventy thousand five hundred and six|US (5) 08/854050|Nineteen million nine hundred and seventy thousand five hundred and nine|US (6) 08/911312|Nineteen million nine hundred and seventy thousand eight hundred and fourteen|US (7) 08/912951|Nineteen million nine hundred and seventy thousand eight hundred and fourteen|US (8) 08/915503|Nineteen million nine hundred and seventy thousand eight hundred and fourteen|U S False: 08/724,643 19961001 US Number: 22 Page: The title page Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: PRIORITY; FROM: 08/724,643;19961001;US TO: (1)08/724,643;19961001;US(2)08/844,419;19970418;US(3)08/846,017;19970425;US(4)08/851,843;19970506;US(5)08/854,050;19970509;US(6)08/911,312;19970814;US(7)08/912,951;19970814;US(8)08/915,503;19970814;US |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1038585 Country of ref document: HK |
|
CX01 | Expiry of patent term |
Granted publication date: 20100602 |
|
CX01 | Expiry of patent term |